

## National Medical Oncology Meeting Farmleigh House

The Fourth annual National Medical Oncology and Haemato-oncology Meeting took place on Friday 3<sup>rd</sup> February 2017 in Farmleigh House.

Over 100 health professionals attended representing the 26 hospitals providing systemic therapy in Ireland.

Ms Ciara Mellett, National Programme Manager for Medical Oncology & Haemato-oncology, NCCP, and Ms Patricia Heckmann, Chief Pharmacist, NCCP, updated delegates on the Systemic Therapy Programme projects:



L to R: Prof Elisabeth Vandenberghe, Chair IHS & Consultant Haematologist St James'; Ms Ciara Mellett, Nat. Prog. Mgr, NCCP; Dr Jerome Coffey, Director, NCCP; Ms Patricia Heckmann, Chief Pharmacist, NCCP; Dr Deirdre O'Mahony, President ISMO & Consultant Medical Oncologist CUF; Dr Miriam O'Connor, Consultant Medical Oncologist, UHW

- Oncology Medication Safety Review
- Cancer Drug Funding
- Model of Care
- Haematology EAG
- MOCIS
- Chemotherapy Protocols
- Standardisation Working Group
- Dose Banding
- ACU Capacity Planning
- NCCP communications

The plenary session, panel discussion, and breakout workshops gave delegates the opportunity to discuss topics of relevance to them.

The NCCP would like to thank all those who attended the conference and participated in the workshops.

A more detailed conference report will be circulated in the coming months.

## New Drugs Funded

Trifluridine and Tiptacil [Lonsurf®] Therapy	February 2017
Nintedanib [Vargatef®]	February 2017
Idelalisib [Zydelig®]	January 2017
Ceritinib [Zykadia®]	December 2016
Ponatinib [Iclusig®]	December 2016

For full list of funded drugs and related indications please visit the NCCP website at <http://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/cdmp/new.html>

## Telephone Triage

The NCCP Oncology Medication Safety Review (2014) recommended (rec. 64) that all units involved in the prescribing and administration of systemic anticancer therapy should have a telephone triage policy in place.

A working group was established and following a review of international practice they favoured the adoption of the UKONS (UK Oncology Nursing Society) Oncology/Haematology Telephone Triage tool kit for use across the 25 adult hospitals in Ireland involved in the administration of SACT.

Nurses working within the cancer services attended training workshops in the NCCP facilitated by a Nurse Advisor from UKONS. As part of the implementation process they will train their colleagues on the use of this tool.

This validated tool uses a Red, Amber and Green scoring system to identify and prioritise the presenting problems of patients who contact the advice lines for assessment and advice.

Aims and objectives of a telephone triage system:

- Improve patient safety and care by ensuring that patients receive a robust, reliable assessment (triage) every time they contact a helpline for advice. **Consistency**
- Those assessments (triage) are of a consistent quality and use an evidence-based assessment (triage) tool. **Evidence based**
- That management and advice is appropriate to the patients "level of risk". This will ensure that those patients who require urgent assessment in an acute area are identified and that action is taken, but also to identify and reassure those patients who are at lower risk and may safely be managed by the primary care team or a planned clinical review and avoid unnecessary attendance. **Appropriate**
- To develop guidelines that would form the basis of triage training and competency assessment for practitioners. **Educational**



## In Brief

### Public Consultations

Thank you to all who provided feedback on recent consultations on our website, including:

- Guidance on the Retention and Disposal of SACT prescriptions and worksheets.
- Extravasation Assessment and Care Record and Baseline Nursing Assessment and Education Record - nursing documents for standardisation.
- Capacity Planning Toolkit.


Post consultation documentation will be available on the NCCP website in the coming months.

### MOCIS

The contract for the delivery of the MOCIS system has been finalised. Several working groups are in place, drawing on medical, nursing, pharmacy, management, and clerical/admin. representatives from across the hospitals. These groups are progressing the “blue print” design of the system to inform configuration. Work is also continuing on standardisation of processes and documentation for the system.

### Final Oncology Medication Safety Review Implementation Status Report

Given the significant progress made by hospitals in implementing the recommendations of the [Oncology Medication Safety Review Report 2014](#), the NCCP has determined that ongoing monitoring of implementation is now appropriately in place in each of the hospitals.



The NCCP's final review of the recommendations at hospital level has been completed. It is now available to download from the NCCP website at <http://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/safetyreview/>

## NCCP Drug Protocols

The NCCP develops chemotherapy protocols to support safe, evidence-based and cost-effective cancer treatment for all cancer patients in Ireland in line with the requirements of the 2006 National Cancer Strategy. A list of all approved protocols can be found on the NCCP website at:

<http://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/>

Recent Protocols published to the website include:

Breast	Carboplatin (AUC6) and Weekly Paclitaxel (80mg/m <sup>2</sup> ) followed by Dose dense DOXorubicin Cyclophosphamide Therapy-Triple Negative Breast Cancer Therapy
	Cyclophosphamide (oral) Methotrexate and 5-Fluorouracil (CMF) Therapy
	Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) Therapy 21 day
	Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) Therapy 28 day
	Exemestane Monotherapy
	Fulvestrant Monotherapy
Gastrointestinal	Letrozole Monotherapy
	DOXOrubicin 60mg/m <sup>2</sup> Therapy
	Epirubicin, Cisplatin and Capecitabine (ECX) Therapy
	Gemcitabine + Capecitabine Therapy
	Gemcitabine + CISplatin Therapy
	Panitumumab 6mg/kg Therapy
Genitourinary-Bladder	Trifluridine and Tipracil (Lonsurf®) Therapy
	CISplatin 40mg/m <sup>2</sup> Weekly with Radiotherapy (RT)
Gynaecology-Cervical	CISplatin 40mg/m <sup>2</sup> Weekly with Radiotherapy (RT)
Gynaecology-Ovarian	Trabectedin and Pegylated Liposomal Doxorubicin (PLD) Therapy
Leukaemia/BMT	Idelalisib Monotherapy
	Idelalisib and RiTUXimab Therapy
	Idelalisib and Ofatumumab Therapy
	Ponatinib Therapy
Lung	Ceritinib Monotherapy
	Oral Etoposide Therapy
	Nintedanib Therapy
Lymphoma & Myeloma	ABVD Therapy
	RiTUXimab 375mg/m <sup>2</sup> Therapy-Follicular Lymphoma
Neuro-oncology	Procarbazine Lomustine and VinCRISTine (PCV) Therapy
Sarcoma	DOXOrubicin (60) and Ifosfamide Therapy
	DOXOrubicin (75) and Ifosfamide Therapy
	Trabectedin Monotherapy